Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials.
AuthorsFallowfield, Lesley J
Powles, Trevor J
AffiliationCancer Research Campaign Psychosocial Oncology Group, University of Sussex, United Kingdom. email@example.com
MetadataShow full item record
AbstractPURPOSE: The purpose of this study was to evaluate the psychosocial implications of tamoxifen versus placebo in women who are at increased risk of breast cancer. PATIENTS AND METHODS: The 488 women in the psychosocial study were recruited from participants in two placebo-controlled, double-blind, randomized, controlled trials that investigated the efficacy of tamoxifen in the prevention of breast cancer in women who are at high familial risk. During a 5-year period, repeated assessments were made of anxiety, psychological distress, and sexual functioning using standardized questionnaires before treatment at baseline and at 6-month intervals during the trial. RESULTS: Questionnaire completion over 5 years was good, with 71.1% of women returning at least 8 of 10 follow-up assessments. Although scores from individuals showed considerable fluctuation and variation over time, changes in anxiety, mood, and sexual functioning were not associated with treatment group. The number of symptoms reported at 48 months via a self-report checklist were not associated with treatment group, but vasomotor symptoms were more frequent among tamoxifen-treated women. Symptoms of low energy, breast sensitivity, and visual blurring were reported most frequently in the placebo group. CONCLUSION: In general, these results are comparable to those from the National Surgical Adjuvant Breast and Bowel Project psychosocial study despite differences in study populations, methodology, and instruments. The long-term use of tamoxifen and other selective estrogen response modulators as preventive agents in high-risk groups has been questioned, but we found no evidence of treatment-related side effects that affect women's psychosocial and sexual functioning.
CitationTamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. 2001, 19 (7):1885-92 J. Clin. Oncol.
JournalJournal of Clinical Oncology
- Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
- Authors: Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B
- Issue date: 1999 Sep
- Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
- Authors: Land SR, Wickerham DL, Costantino JP, Ritter MW, Vogel VG, Lee M, Pajon ER, Wade JL 3rd, Dakhil S, Lockhart JB Jr, Wolmark N, Ganz PA
- Issue date: 2006 Jun 21
- Cognitive functioning during long-term tamoxifen treatment in postmenopausal women with breast cancer.
- Authors: Boele FW, Schilder CM, de Roode ML, Deijen JB, Schagen SB
- Issue date: 2015 Jan
- Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study.
- Authors: Day R, Ganz PA, Costantino JP
- Issue date: 2001 Nov 7
- Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
- Authors: Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, International Breast Cancer Intervention Study I Investigators.
- Issue date: 2007 Feb 21